U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Osimertinib (Tagrisso): CADTH Reimbursement Review: Therapeutic area: Non–small cell lung cancer [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Mar.

Cover of Osimertinib (Tagrisso)

Osimertinib (Tagrisso): CADTH Reimbursement Review: Therapeutic area: Non–small cell lung cancer [Internet].

Show details
DFS in patients with stage II to stage IIIA disease was tested first using the full 2-side 5% alpha. If statistical significance was shown for DFS in the stage II to stage IIIA population, DFS in the overall population would be tested. If the DFS results in both the stage II to stage IIIA population and the overall population were statistically significant, OS would then be assessed first in the stage II to stage IIIA population, and then in the overall population if statistical significance was reached in the stage II to stage IIIA population.

Figure 3Multiple-Testing Procedure in the ADAURA Trial

Source: ADAURA study protocol.12

DFS = disease-free survival; OS = overall survival.

From: Clinical Review

Copyright © 2022 Canadian Agency for Drugs and Technologies in Health.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Contents

Views

  • Cite this Page
  • PDF version of this title (6.1M)

Other titles in this collection

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...